The purpose of this work was to modernize recommendations for evaluation, staging, and
response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (…

The purpose of these guidelines is to assist physicians in recommending, performing, interpreting
and reporting the results of FDG PET/CT for oncological imaging of adult patients. PET …

Purpose Recent advances in imaging, use of prognostic indices, and molecular profiling
techniques have the potential to improve disease characterization and outcomes in lymphoma. …

Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs
used daily in oncology include clinical TNM stage, objective response and left ventricular …

Background We tested interim positron-emission tomography–computed tomography (PET-CT)
as a measure of early response to chemotherapy in order to guide treatment for patients …

Background It is unclear whether patients with early-stage Hodgkin’s lymphoma and negative
findings on positron-emission tomography (PET) after three cycles of chemotherapy with …

Uniformly adopted response criteria are essential for assessment of therapies incorporating
conventional chemotherapy and chemoimmunotherapy regimens. Recently, …

Purpose To determine if PET reporting criteria for the Response Adapted Treatment in Hodgkin
Lymphoma (RATHL) trial could enable satisfactory agreement to be reached between ‘…

Positron emission tomography (PET) is a whole-body imaging technique using 18 fluorine-fluorodeoxyglucose
(FDG), whose uptake is increased in tumor cells. Published studies have …

At present, there are no standard criteria that have been validated for interim PET reporting
in lymphoma. In 2009, an international workshop attended by hematologists and nuclear …